FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileTRex Bio Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TRXB
TRex Bio Inc. Stock AnalysisComprehensive stock analysis for TRex Bio Inc. (TRXB) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTRXB
TRXB
TRex Bio Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TRXB
  1. Home
  2. Stocks
  3. TRex Bio Inc.
TB

TRex Bio Inc.

🇺🇸TRXB•NASDAQ
TB

TRex Bio Inc.

🇺🇸TRXB•NASDAQ
Market cap
$78.22M
Sentiment

Your view on TRXB

Mkt Cap
$78.22M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About TRex Bio Inc.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Marion Johnston Erwin
Headquarters
269 E. Grand Ave., Suite 300, South San Francisco, CA, US
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Marion Johnston Erwin
Headquarters
269 E. Grand Ave., Suite 300, South San Francisco, CA, US
Description

Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines.

The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for TRex Bio Inc. from FRC's valuation model, read against the market price. TRXB last traded at $9.39; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for TRex Bio Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for TRex Bio Inc.. TRex Bio Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for TRex Bio Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 19, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate-$0.66-$0.53-$4.28-$2.17
Low estimate-$0.80-$0.53-$5.89-$2.48
High estimate-$0.53-$0.53-$2.84-$1.73
No. of analysts1122
Year-ago EPS————
Growth————

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.00$0.00$0.00$0.00
Low estimate$0.00$0.00$0.00$0.00
High estimate$0.00$0.00$0.00$0.00
No. of analysts0000
Year-ago revenue————
Growth————

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 19, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for TRex Bio Inc.. TRex Bio Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold TRXB12 companies · 8 funds

More Medical - Pharmaceuticals companies

Market cap

  • PBHPrestige Consumer Healthcare Inc.NYSE$2.4B
  • PKBFFPeakBirch Commerce Inc.OTC$545M
  • PLWYPeoplesway.com Inc.OTC$1,508
  • PNDHFPond Technologies Holdings Inc.OTC$684,738
  • PNPLPineapple, Inc.OTC$6M
  • POMPOMDOCTOR LtdNASDAQ$14M
  • PRPHProPhase Labs, Inc.NASDAQ$331,590
  • PXYNPraxsyn CorporationOTC$6,347
  • QMDTQuick-Med Technologies, Inc.OTC$11,204
  • RADLYRaia Drogasil S.A.OTC$8.8B
  • RBIIRising BioSciences, Inc.OTC$4,991
  • RCDTFRecordati Industria Chimica e Farmaceutica S.p.A.OTC$11.6B

ETFs holding TRex Bio Inc.

% of the fund

  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • VTWOVanguard Russell 2000 ETF$16.6B in assets0.00%
  • VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.00%
  • VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.00%
  • VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
  • VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
  • VTHRVanguard Russell 3000 ETF$4.9B in assets0.00%

Largest holders first, then the funds most concentrated in TRXB.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold TRex Bio Inc., and how their positions are changing. At a $78.2M market value, institutional positions materially move TRex Bio Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by TRex Bio Inc. executives and directors. Shares of TRex Bio Inc. have traded between $9.06 and $16.56 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming TRex Bio Inc.. TRex Bio Inc. is a $78.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming TRex Bio Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for TRex Bio Inc.. Coverage tracks TRex Bio Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of TRex Bio Inc.

TRXB Analysis
Fair
Past1
Growth2
Health5
Profit1
Value1

News

Latest Market News